Investor Presentation
112
Investor presentation First six months of 2022
EMEA at a glance
EMEA
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
300
DKK
billion
25%
First half of 2022
Sales
(mDKK)
Growth²
Total GLP-13
6,815
35%
250
100
80%
19%
I
GLP-1
Long-acting insulin4
3,776
7%
I
33.0%¹
Premix insulin5
1,348
-11%
200
80
60%
Fast-acting insulin
3,391
2%
150
60
60
Human insulin
3.2%1
1,043
-8%
Insulin
260
40%
Total insulin
9,558
1%
100
40
195
Other Diabetes care?
361
3%
158
50
20
OAD
20
11.1%1
20%
Diabetes care
16,734
12%
Obesity care8
1,516
78%
0
0
0%
2021
2030
2045
May
2017
May
2022
Diabetes & Obesity
18,250
16%
care
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
Rare disease⁹
Total
3,489
-5%
21,739
12%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
May 2022: Novo Nordisk 48%, Sanofi 32% and Eli Lilly 16%; Competitor GLP-1
value market shares, as of May 2022: Novo Nordisk 59%, Eli Lilly 38% and
AstraZeneca 3%; OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT,
May 2022 value figures
2 At Constant exchange rates; 3 Comprises VictozaⓇ, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises RyzodegⓇ and
NovoMix®: 6 Comprises FiaspⓇ and NovoRapid®: 7 Comprises Novo NormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®: 9 Comprises
primarily NovoSeven®, Novo Eight® NovoThirteen®, Esperoct®, Refixia®,
Norditropin, Vagifem® and ActivelleⓇ
Source: Quarterly company announcementView entire presentation